Hi, what are you looking for?

Thank you everyone, for joining us today. We continued to deliver strong growth in our top line revenue this quarter, and we are pleased to report record commercial RECELL revenues, which exclude BARDA revenue, of $8.2 million dollars, compared to $6.7 million dollars, a 23% increase, over the same quarter last year. Our commercial revenue was $15.7 million in the half-year ending June 30, 2022, an increase of $4.4 million or 39%, compared to $11.3 million in the corresponding period in the prior year.

To view the full announcement, including downloadable images, bios, and more, click here.

Click image above to view full announcement.

ABOUT AVITA MEDICAL, INC. AVITA Medical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL® System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells. Delivered at the point-of-care, RECELL enables improved clinical outcomes and validated cost savings. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications, including acute traumatic wounds and repigmentation of stable vitiligo lesions.

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational, and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

The twinning of machine learning algorithms and laboratory testing can aid in the acceleration of discovering new antimicrobials.

This warning also serves as a reminder that infrastructure devices must be included in vulnerability management programs.

The entire useless multi-decades-long argument boils down to one thing – Do you believe in thermodynamics, yes or no?

China has stepped up spending on coal in the face of extreme weather, a domestic energy crunch and rising global fuel prices.

COPYRIGHT © 1998 - 2022 DIGITAL JOURNAL INC. Sitemaps: XML / News . Digital Journal is not responsible for the content of external sites. Read more about our external linking.